Canada· CA-DIN-02495058
XOSPATA
A gilteritinib product containing gilteritinib (gilteritinib fumarate), registered in Canada by ASTELLAS PHARMA CANADA INC. The same ATC class is registered in 13 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Gilteritinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX13 (gilteritinib), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 8 of them publish a price we can compare per daily dose
Gilteritinib · ATC L01EX13
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of gilteritinib costs, country by country.
Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Gilteritinib · price per daily dose (0.12 g)
USD · FX 28 Sept 2026
- CH Switzerland$662.17
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- GILTERITINIB (GILTERITINIB FUMARATE)
- Manufacturer
- ASTELLAS PHARMA CANADA INC
- Country
- Canada (CA)
- ATC code
- L01EX13
- ATC class
- Gilteritinib
- Defined daily dose
- 0.12 g, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
529 interactions on record for gilteritinib.
Graded by severity as the source publishes them — 116 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gilteritinib · interactions on record
529 records
- 116 severe
- 408 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Gilteritinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomGilteritinib 40mg tabletsAstellas Pharma Ltd
- United StatesXospataAstellas Pharma US, Inc.
- CzechiaXOSPATAAstellas Pharma Europe B.V., Leiden
- SpainXOSPATA 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstellas Pharma Europe B.V.
- FinlandXospataAstellas Pharma Europe B.V.
- FranceXOSPATA 40 mg, comprimé pelliculéASTELLAS PHARMA EUROPE (PAYS-BAS)
- BelgiumXospata 40 mgAstellas Pharma Europe
- IrelandXospata 40 mg film-coated tabletsAstellas Pharma Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Xospata
- Liechtenstein · Xospata
- Norway · Xospata
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2d40d192-a2b5-44b7-8c1d-32bd3c4cd537 GET /v1/drugs/2d40d192-a2b5-44b7-8c1d-32bd3c4cd537?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02495058",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L01EX13",
"schedule": [
"Prescription"
],
"drug_code": "98500",
"strengths": [
"40 MG"
],
"ahfs_class": null,
"substances": [
"GILTERITINIB (GILTERITINIB FUMARATE)"
],
"product_categorization": null
}See everything about gilteritinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.